102 related articles for article (PubMed ID: 38715492)
1. [The present and future of allogeneic hematopoietic stem cell transplantation for mantle cell lymphoma].
Liu Y; Huang XJ; Mo XD
Zhonghua Nei Ke Za Zhi; 2024 May; 63(5):512-516. PubMed ID: 38715492
[TBL] [Abstract][Full Text] [Related]
2. Double autologous stem cell transplantation in mantle cell lymphoma.
Bolaman Z; Kadikoylu G; Barutca S; Senturk T
Transplantation; 2002 Sep; 74(6):902-3. PubMed ID: 12364880
[No Abstract] [Full Text] [Related]
3. Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma?
Shah NN; Hamadani M
J Clin Oncol; 2021 Feb; 39(5):487-498. PubMed ID: 33434076
[No Abstract] [Full Text] [Related]
4. Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic review.
Kharfan-Dabaja MA; Reljic T; El-Asmar J; Nishihori T; Ayala E; Hamadani M; Kumar A
Future Oncol; 2016 Nov; 12(22):2631-2642. PubMed ID: 27381652
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic stem cell transplantation for mantle cell lymphoma--does it deserve a better look?
Rifkind J; Mollee P; Messner HA; Lipton JH
Leuk Lymphoma; 2005 Feb; 46(2):217-23. PubMed ID: 15621804
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations.
Lin RJ; Ho C; Hilden PD; Barker JN; Giralt SA; Hamlin PA; Jakubowski AA; Castro-Malaspina HR; Robinson KS; Papadopoulos EB; Perales MA; Sauter CS
Br J Haematol; 2019 Mar; 184(6):1006-1010. PubMed ID: 30537212
[TBL] [Abstract][Full Text] [Related]
7. Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?
Atilla E; Atilla PA; Demirer T
Int J Hematol; 2017 Mar; 105(3):257-264. PubMed ID: 27995456
[TBL] [Abstract][Full Text] [Related]
8. Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory mantle cell lymphoma.
Yamasaki S; Chihara D; Kim SW; Izutsu K; Iwato K; Fukuda T; Uchida N; Amano I; Nakazawa H; Kuroda J; Hashimoto H; Ichinohe T; Kanda Y; Atsuta Y; Suzumiya J; Suzuki R
Ann Hematol; 2018 Aug; 97(8):1445-1452. PubMed ID: 29610968
[TBL] [Abstract][Full Text] [Related]
9. Treatment of mantle cell lymphoma: current approach and future directions.
Brody J; Advani R
Crit Rev Oncol Hematol; 2006 Jun; 58(3):257-65. PubMed ID: 16751087
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients.
Fenske TS; Hamadani M; Cohen JB; Costa LJ; Kahl BS; Evens AM; Hamlin PA; Lazarus HM; Petersdorf E; Bredeson C
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1543-1551. PubMed ID: 27131863
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic stem cell transplantation in mantle cell lymphoma.
Ganti AK; Bierman PJ; Lynch JC; Bociek RG; Vose JM; Armitage JO
Ann Oncol; 2005 Apr; 16(4):618-24. PubMed ID: 15781489
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma.
Gauthier J; Maloney DG
Hematol Oncol Clin North Am; 2020 Oct; 34(5):957-970. PubMed ID: 32861289
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy.
Khouri IF; Lee MS; Romaguera J; Mirza N; Kantarjian H; Korbling M; Albitar M; Giralt S; Samuels B; Anderlini P; Rodriguez J; von Wolff B; Gajewski J; Cabanillas F; Champlin R
Ann Oncol; 1999 Nov; 10(11):1293-9. PubMed ID: 10631455
[TBL] [Abstract][Full Text] [Related]
14. Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
Vaughn JE; Sorror ML; Storer BE; Chauncey TR; Pulsipher MA; Maziarz RT; Maris MB; Hari P; Laport GG; Franke GN; Agura ED; Langston AA; Rezvani AR; Storb R; Sandmaier BM; Maloney DG
Cancer; 2015 Oct; 121(20):3709-16. PubMed ID: 26207349
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma.
Maris MB; Sandmaier BM; Storer BE; Chauncey T; Stuart MJ; Maziarz RT; Agura E; Langston AA; Pulsipher M; Storb R; Maloney DG
Blood; 2004 Dec; 104(12):3535-42. PubMed ID: 15304387
[TBL] [Abstract][Full Text] [Related]
16. Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation.
Martínez C; Carreras E; Rovira M; Urbano-Ispizua A; Esteve J; Perales M; Fernández F; Montserrat E
Bone Marrow Transplant; 2000 Sep; 26(6):677-9. PubMed ID: 11035375
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma.
Rule S; Cook G; Russell NH; Hunter A; Robinson S; Morley N; Sureda A; Patrick P; Clifton-Hadley L; Adedayo T; Kirkwood A; Peggs KS
Br J Haematol; 2019 Mar; 184(6):999-1005. PubMed ID: 30560573
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic hematopoietic stem cell transplantation for lymphoma.
Dean RM; Bishop MR
Clin Lymphoma; 2004 Mar; 4(4):238-49. PubMed ID: 15072616
[TBL] [Abstract][Full Text] [Related]
19. T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease.
Lew TE; Cliff ERS; Dickinson M; Tam CS; Seymour JF; Blombery P; Bajel A; Ritchie D; Khot A
Bone Marrow Transplant; 2021 Nov; 56(11):2857-2859. PubMed ID: 34285380
[No Abstract] [Full Text] [Related]
20. CAR T-cell therapy versus allogeneic HSCT for relapsed or refractory mantle cell lymphoma.
Iacoboni G; Dietrich S; Liebers N
Lancet Haematol; 2023 Dec; 10(12):e951-e952. PubMed ID: 38030316
[No Abstract] [Full Text] [Related]
[Next] [New Search]
